What's Happening?
A clinical trial conducted in 2025 has found that semaglutide, the active ingredient in Ozempic, can reduce measurable biological age in adults by approximately 3 to 5 years. The trial, led by Michael J. Corley of UC San Diego, involved 108 adults with
HIV-associated lipohypertrophy and demonstrated improvements in inflammation, cardiovascular health, and kidney function. The study used DNA methylation patterns to measure biological age, showing significant reductions in biological age markers. The findings suggest that semaglutide, originally designed for diabetes and obesity management, may also have potential as a longevity drug.
Why It's Important?
The implications of semaglutide's potential to extend healthspan are substantial, as it could become one of the first medications to formally extend human healthspan beyond treating specific conditions. This could lead to a paradigm shift in how aging is managed, with semaglutide and similar drugs being prescribed not just for diabetes and obesity but also for their potential anti-aging effects. The trial's results add to the growing body of evidence supporting the use of GLP-1 receptor agonists as candidate longevity drugs, potentially impacting healthcare practices and insurance coverage.
What's Next?
Further research is needed to confirm semaglutide's effects on biological aging in broader populations. Ongoing and future trials will determine whether semaglutide can be routinely prescribed for aging-related benefits. If the findings hold up, semaglutide could become a widely used drug for extending healthspan, influencing healthcare policies and practices. The next several years of research will be crucial in establishing semaglutide's role in longevity medicine.
